Eligard Information Center
Eligard Information Center

Not an actual patient.

ELIGARD® is a proven, reliable, and trusted ADT

Proven efficacy supported by the strongest body of clinical data published in peer-reviewed journals1-7

Backed by an established reputation for advancing the science of prostate cancer*

line-svg
16
manuscripts
published
line-svg
110+
posters & oral 
presentations at medical congresses
line-svg
2
MANUSCRIPTS in progress
line-svg
190+
abstracts
*Research supported by Tolmar, Inc.
ELIGARD CONTINUES TO LEAD THE WAY IN BRINGING CURRENT AND RELEVANT SCIENCE TO THE ADVANCED PROSTATE CANCER COMMUNITY

ELIGARD ACHIEVED PROFOUND T SUPPRESSION ACROSS 1-, 3-, 4-, AND 6-MONTH DOSES

Percentage of Patients Achieving Serum Testosterone Concentrations
 of ≤20 ng/dL Across All Studies2†
Graph showing percentages of patients who achieved serum testosterone concentrations of ≤20 ng/dL across all studies
†Data from week 3 time point excluded as it reflects initial T surge and not final levels of suppression.1
line-svg
by day 28
94-99%

of patients achieved T levels ≤50 ng/dL across all doses1

line-svg
at week 24
92-96%

of patients achieved T levels <20 ng/dL across all doses2

Mean Testosterone Level (ng/dL)
 Achieved Across All Doses at Study Conclusion2

low occurrence of T BREAKTHROUGHS

line-svg
In the ELIGARD study population, Only
2
OUT OF
424
had T breakthroughs‡ after the second dose at the 24-week time point1,3
Achieve your PSA goals with ELIGARD1
line-svg

In all studies, ELIGARD decreased serum PSA in all patients whose baseline values were elevated above normal

line-svg
91-95%

of patients achieved normal PSA values at study conclusion

PSA LEVELS ARE A GOOD INDICATOR OF DISEASE PROGRESSION, BUT MEASURING T LEVELS ENSURES YOUR PATIENTS CONTINUE TO ACHIEVE THE GOALS OF ADT3,8
Analysis includes 424 patients who achieved castrate T levels by the second dose on the 1-month (n=113), 3-month (n=115), 4-month (n=88), and 6-month (n=108) formulations. Of 424 patients, 2 experienced breakthroughs with peak T >50 ng/dL.3
‡A breakthrough is defined as a T surge of >50 ng/dL.1

The importance of nadir T suppression

Low nadir T levels matter in ADT
  • Multiple studies highlight the importance of nadir T during androgen deprivation therapy9-11
  • Leuprolide acetate, the active ingredient in ELIGARD, has been confirmed to achieve and maintain low T levels,
 with 80% of patients reaching nadir T ≤3 ng/dL when injected subcutaneously3
Current science doesn’t just reflect T targets of <20 ng/dL. It also considers lowest T levels during treatment, also known as nadir T3
91% of patients achieved T levels of ≤5 ng/dL and 97% achieved T levels of ≤10 ng/dL

A WELL-ESTABLISHED SAFETY PROFILE

Adverse Events for ELIGARD1§
Most common adverse events that occurred for each dose of ELIGARD
§A single event reported as moderate pain resolved within 2 minutes and all 3 mild pain events resolved within several days following injection of ELIGARD 30 mg.1
‖Transient pain was reported as mild in intensity in 9 of 10 (90%) events and moderate in intensity in 1 of 10 (10%) events following injection of ELIGARD 45 mg.1
YOUR PATIENTS RECEIVING SUBCUTANEOUS INJECTIONS MAY REPORT IMMEDIATE TEMPORARY PAIN AT THE INJECTION SITE, UNLIKE PATIENTS RECEIVING INTRAMUSCULAR INJECTIONS, WHO MAY FEEL MUSCLE PAIN THE DAY AFTER1,12
Over 40 years of efficacy and safety data of leuprolide acetate show a well-established safety profile, with no known drug–drug interactions13
Prostate cancer patients have a high risk of potential drug–drug interactions (DDIs) due to the use of treatment combinations, anti-cancer therapies, and the likelihood of comorbid conditions that require drug therapy.14
DDIs have been reported for GnRH antagonists, anti-androgens, PARP inhibitors, and taxanes, but none are expected for certain GnRH agonists, including leuprolide acetate.15
ADT, androgen deprivation therapy; PSA, prostate-specific antigen; T, testosterone.

get more WITH ELIGARD, INCLUDING A dosing schedule that works for you and your patients

LEARN MORE
References: 1. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2024. 2. Shore ND, Chu F, Moul J, et al. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int. 2017;119(2):239-244. 3. Pieczonka CM, Twardowski P, Renzulli J 2nd, et al. Effectiveness of subcutaneously administered leuprolide acetate to achieve low nadir testosterone in prostate cancer patients. Rev Urol. 2018;20(2):63-68. 4. Crawford ED, Hafron JM, Tagawa ST, et al. Impact of late dosing on testosterone suppression with 2 different leuprolide acetate formulations: in situ gel and microsphere. an analysis of United States clinical data. J Urol. 2021;205(2):554-560. 5. Saltzstein D, Shore ND, Moul JW, et al. Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Ther Adv Urol. 2017;10(2):43-50. 6. Sartor O. Eligard®: a new form of treatment for prostate cancer. Eur Urol Open Sci. 2006;5(18):P905-P910. 7. Data on file. Tolmar, Inc. 2024. 8. Rosario DJ, Davey P, Green J, et al. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol. 2016;34(12):1601-1609. 9. Bryant AK, McKay RR, Kader AK, et al. Subcastrate testosterone nadir and clinical outcomes in intermediate- or high-risk localized prostate cancer. Int J Radiat Oncol Biol Phys. 2019;103(5):1068-1076. 10. Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33(10):1151-1156. 11. Kamada S, Sakamoto S, Ando K, et al. Nadir testosterone after long-term followup predicts prognosis in patients with prostate cancer treated with combined androgen blockade. J Urol. 2015;194(5):1264-1270. 12. Prettyman J, Engel L, Boldt-Houle DM, Atkinson S, Wilt W. Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urologic Nursing. 2019;39(2):83-99. 13. Lupron Depot (leuprolide acetate). Prescribing Information. AbbVie, Inc. 2023. 14. Spratt DE, Shore N, Sartor O, Rathkopf D, Olivier K. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):647-661. 15. Ruplin A, Segal E, McFarlane T. Review of drug-drug interactions in patients with prostate cancer. J Oncol Pharm Pract. Published online May 8, 2024.
Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.
ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.
To report SUSPECTED ADVERSE REACTIONS, contact Tolmar at ​1-​888​-354​-4273 or FDA at ​1​-800-​FDA-​1088​ or www.fda.gov/medwatch.
Please see full Prescribing Information for ELIGARD or full Prescribing Information for ELIGARD Pre-Connected Syringe System.
Eligard Information Center

You are now leaving
ELIGARDhcp.COM

Are you sure you want to leave? 

continue to site
cancel
Skip to content